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Background: Gallbladder cancer (GBC) is a leading cause of cancer-related death worldwide, and its prognosis
remains poor, with 5-year survival of approximately 5%. In this study, we analyzed the involvement of a novel
proteoglycan, Sparc/osteonectin, cwcv, and kazal-like domains proteoglycan 1 (SPOCK1), in the tumor progression
and prognosis of human GBC.
Methods: SPOCK1 expression levels were measured in fresh samples and stored specimens of GBC and adjacent
nontumor tissues. The effect of SPOCK1 on cell growth, DNA replication, migration and invasion were explored by
Cell Counting Kit-8, colony formation, EdU retention assay, wound healing, and transwell migration assays, flow
cytometric analysis, western blotting, and in vivo tumorigenesis and metastasis in nude mice.
Results: SPOCK1 mRNA and protein levels were increased in human GBC tissues compared with those in nontumor
tissues. Immunohistochemical analysis indicated that SPOCK1 levels were increased in tumors that became
metastatic, compared with those that did not, which was significantly associated with histological differentiation
and patients with shorter overall survival periods. Knockdown of SPOCK1 expression by lentivirus-mediated shRNA
transduction resulted in significant inhibition of GBC cell growth, colony formation, DNA replication, and invasion in vitro.
The knockdown cells also formed smaller xenografted tumors than control GBC cells in nude mice. Overexpression of
SPOCK1 had the opposite effects. In addition, SPOCK1 promoted cancer cell migration and epithelial-mesenchymal
transition by regulating the expression of relevant genes. We found that activation of the PI3K/Akt pathway was involved
in the oncogenic functions of SPOCK1 in GBC.
Conclusions: SPOCK1 activates PI3K/Akt signaling to block apoptosis and promote proliferation and metastasis by GBC
cells in vitro and in vivo. Levels of SPOCK1 increase with the progression of human GBC. SPOCK1 acts as an oncogene
and may be a prognostic factor or therapeutic target for patients with GBC.
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Gallbladder cancer (GBC) is the most common biliary
tract malignancy and the seventh most common
gastrointestinal cancer [1]. The Surveillance, Epidemi-
ology, and End Results (SEER) program estimates the
incidence of GBC at 2.5 cases per 1 × 105 people. Des-
pite the relatively low incidence rate, GBC-associated
mortality is higher than that of other cancers [2]. The
prognosis of advanced gallbladder carcinoma is very
poor, and the 5-year survival rate is only approximately
5% [3]. This poor survival rate is because of the early
spread of tumors via lymphatic, perineural, and
hematogenous routes as well as direct invasion into
the liver [4]. Therefore, patient prognoses may be im-
proved by identifying novel and effective therapeutic
targets for the treatment of this disease and increasing
our understanding of biomarkers that can predict
therapeutic responses.
The human genome sequencing project has found that
70% of the genome is transcribed, but only up to 2% of
the human genome serves as blueprints for proteins
[5,6]. One oncogene, sparc/osteonectin, cwcv, and kazal-
like domains proteoglycan 1 (SPOCK1), has been found
to play a critical role in cell-cycle control, apoptosis,
DNA repair, and metastasis [7]. SPOCK1 encodes a matri-
cellular glycoprotein belonging to a novel Ca2+-binding
proteoglycan family. Members of this protein family,
which share a similar N-terminus, follistatin-like domain,
and C-terminus, are involved in cell proliferation, adhe-
sion, and migration [8]. Other members of this family in-
clude SPARC, testican-2, and testican-3. Among these
proteins, SPARC has been well studied in various cancers.
Increasing evidence has emphasized the importance of
SPARC in regulating proliferation, cell-cycle progres-
sion, apoptosis, adhesion, and cell-matrix interactions
[9]. More interestingly, a number of studies have dem-
onstrated that SPOCK1 plays a critical role in prostate
cancer recurrence, glioblastoma invasion, and hepato-
cellular carcinoma progression [10-12]. However, the
underlying mechanism of SPOCK1 overexpression is far
from clear. Even less is known about the function and
mechanism by which SPOCK1 contributes to cancer de-
velopment and progression.
Considering the structural similarity between SPOCK1
and SPARC, it is of great interest to investigate the role of
SPOCK1 in GBC development and progression. In the
present study, we demonstrated a significant correlation
between high expression of SPOCK1 and poor prognoses
of GBC patients, and its oncogene function was examined
further in vitro and in vivo. With a focus on its anti-
apoptotic and epithelial-mesenchymal transition (EMT)
functions, we demonstrated that SPOCK1 acts as a poten-
tial oncogene, which in turn contributes to the initiation
and progression of GBC.Methods
Patients, specimens, and cell lines
This study was approved by the ethics committee of
Xinhua Hospital, and all patients provided informed
consent. Cancer tissue specimens were obtained from 64
GBC patients who underwent radical cholecystectomy
without prior radiotherapy or chemotherapy between
2010 and 2013 at the Department of General Surgery,
Xinhua Hospital, School of Medicine, Shanghai Jiao
Tong University, China. In addition, 60 patients with
cholelithiasis who underwent simple cholecystectomy
were included as controls. All diagnoses of GBC, chole-
lithiasis, and lymph node metastasis were confirmed by
histopathological examination. The tissue specimens had
been fixed in 4% formalin immediately after removal and
embedded in paraffin for immunohistochemical staining.
Fresh GBC tissue samples and paired non-cancerous tis-
sue samples were obtained from 28 GBC patients. These
samples were used for quantitative real-time PCR ana-
lysis (qRT-PCR). Fresh tissues were processed within
15 min after removal. Each sample was frozen and
stored at −80°C. Paired non-cancerous tissues were dis-
sected at least 2 cm away from the tumor border and
were confirmed to lack tumor cells by microscopy.
Among the 64 GC cases, there were 22 males and 42 fe-
males with ages ranging from 44 to 90 years (mean age:
68 years). All specimens and fresh tissue samples had
been confirmed by pathological diagnosis and were
staged according to the 7th AJCC-TNM Classification of
Malignant Tumors. The median follow-up period was
15 months (range, 1–36.5 months).
GBC cell lines GBC-SD, NOZ, SGC-996, OCUG, and
EH-GB-1 were obtained from the Health Science Research
Resources Bank (Osaka, Japan).Immunohistochemical analysis and evaluation of
SPOCK1 expression
Immunohistochemical staining was performed using a
standard immunoperoxidase staining procedure. SPOCK1
expression in benign and malignant specimens was evalu-
ated according to methods described by Pinheiro et al.
[13]. Sections were semi-quantitatively scored for the ex-
tent of immunoreactions as follows: 0, 0% immunoreactive
cells; 1, <5% immunoreactive cells; 2, 5–50% immunoreac-
tive cells; and 3, >50% immunoreactive cells. Additionally,
the staining intensity was semi-quantitatively scored as 0
(negative), 1 (weak), 2 (intermediate), or 3 (strong). The
final immunoreaction score was defined as the sum of both
parameters, and the samples were grouped as negative (0),
weak (1–2), moderate (3), and strong (4–6) staining. For
statistical purposes, only the final immunoreaction scores
of moderate and strong groups were considered as positive,
and the other final scores were considered as negative.
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Total RNA was extracted from tissue samples or cul-
tured cells with Trizol reagent (Takara, Shiga, Japan).
cDNA was synthesized from 2 μg of total RNA using
random primers and M-MLV Reverse Transcriptase
(Invitrogen, Carlsbad, CA). RNA expression was mea-
sured by qRT-PCR using the SYBR-Green method
(Takara) according to the manufacturer’s instructions.
The relative expression level of the target gene was cal-
culated by 2-ΔCT (ΔCT = CT
target-CT
GADPH) and normal-
ized to the relative expression detected in the
corresponding control cells, which was defined as 1.0.
For the correlation study, the expression level (defined
as the fold change) of SPOCK1 was calculated by 2-ΔΔCT
(ΔΔCT = ΔCTtumor-ΔCTnontumor). Primer sequences are
listed in Additional file 1: Table S1.
Lentivirus-mediated RNA interference
The short hairpin RNAs (shRNAs) [14] which listed in
Additional file 1: Table S1 were used to target SPOCK1.
The sequence of the negative control shRNA was 5′-TT
CTCCGAACGTGTCACGT-3′. shSPOCK1-1 and nega-
tive control shRNA were synthesized and inserted into
the pFH1UGW lentivirus core vector containing a
cytomegalovirus-driven enhanced green fluorescent
protein (EGFP) reporter gene. Expression of the shRNA
was driven by the H1 promoter. Recombinant lentivi-
ruses expressing SPOCK1-shRNA or negative control
shRNA (Lv-shSPOCK1 and Lv-shNC, respectively) were
produced by Genechem (Shanghai, China). GBC-SD
and NOZ cells were infected with concentrated virus in
serum-free medium. The supernatant was replaced with
complete culture medium after 24 h. SPOCK1 expres-
sion in the infected cells was validated by qRT-PCR ana-
lysis and western blot assays after 120 h.
Construction of plasmids and transfection
The full-length SPOCK1 cDNA (nt 152–1471; GenBank
accession number NM_004598) was cloned into the
GV143 expression vector (Genechem, Shanghai, China)
and transfected into SGC-996 cells. Stable SPOCK1-
expressing clones were selected for 2 weeks using neo-
mycin (Genechem), and the expression level of SPOCK1
was determined by qRT-PCR and western blot assays.
Empty vector-transfected cells (MOCK) were used as
control. Primer sequences for vectors construction are
listed in Additional file 1: Table S1.
In vitro tumorigenesis assays
A Cell Counting Kit-8 (CCK-8; Dojindo) cell prolifera-
tion assay was performed according to the manufac-
turer’s instructions. Anchorage-independent growth was
assessed by a colony formation assay. Briefly, 500 cells
were seeded in 6-well plates. The cells were cultured forapproximately 14 days, fixed with 4% paraformaldehyde,
and stained with 0.1% crystal violet (Sigma, St. Louis,
MO). The total number of colonies (>50 cells/colony)
was counted. Edu retention assays were performed to
examine the effect of SPOCK1 on DNA replication. Dis-
sociated cells were exposed to 25 μM of 5-ethynyl-2′-
deoxyuridine (Edu, RiboBio, Guangzhou, China) for 2 hr
at 37°C, and then the cells were fixed in 4% paraformal-
dehyde. After permeabilization with 0.5% Triton-X, the
cells were reacted with 1× Apollo reaction cocktail
(RiboBio) for 30 min. Subsequently, the DNA contents
of the cells were stained with Hoechst 33342 for 30 min
and visualized under a fluorescence microscope. The ex-
periments were performed in triplicate.
In vitro migration and invasion assays
For the in vitro wound-healing assay, a cell-free area of
the culture medium was wounded by scratching with a
200-μL pipette tip. Cell migration into the wound area
was monitored in serum-free medium and photographed
under a fluorescence microscope at 0 and 48 h. Cell
migration and invasion were examined using 8-μm
transwell filters (BD Biosciences, Franklin Lakes, NJ).
GBC-SD (3 × 104), NOZ (4 × 104) cells, and SGC-996
(8 × 104) in 0.5 μL serum-free medium were added to
the upper chamber containing an uncoated or Matrigel
(BD Biosciences)-coated membrane. The lower chamber
was filled with 500 μL basal medium with 10% fetal bo-
vine serum (FBS). After 24 h of incubation at 37°C in a
humidified 5% CO2 incubator, cells that migrated to the
lower compartment were fixed with methanol and
stained with crystal violet. Migrated or invaded cells
were counted in five randomly chosen fields in each
well. Imaging and cell counting were performed at × 10
magnification under a fluorescence microscope. The ex-
periments were performed in triplicate.
Subcutaneous and peritoneal xenograft models
Nude nu/nu mice, 4–6 weeks old, were purchased from
the Shanghai Laboratory Animal Center of the Chinese
Academy of Sciences (Shanghai, China). All mice were
housed in specific pathogen-free conditions following the
guidelines of the Ethics Committee of Xinhua Hospital,
School of Medicine, Shanghai Jiaotong University. To ex-
plore the effects of SPOCK1 on tumor growth in vivo,
cells were subcutaneously injected into the left axilla of
the mice (five mice/group). Tumor growth was monitored
every week and measured in two dimensions. The tumor
volume was calculated using the following formula: tumor
volume = 4π/3 × (width/2)2 × (length/2), where the width
and length were the shortest and longest diameters, re-
spectively. After 4 weeks, the mice were sacrificed and the
tumors were dissected out and weighed. The proliferative
index of Ki-67 was evaluated in xenograft tumors by
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tigating the effects of SPOCK1 on tumor metastasis in vivo,
1 × 105 NOZ cells (Lv-shNC and Lv-shSPOCK1) were sus-
pended in 1 mL serum-free medium and peritoneally
injected into five mice. After 4 weeks, the mice were sacri-
ficed and the peritoneal tumors were collected for IHC.
Immunofluorescence analysis
Cells were seeded in 6-well plates and cultured over-
night. Then, the cells were fixed in 3.5% paraformalde-
hyde and permeabilized in a solution of 0.1% bovine
serum albumin (BSA) and 0.5% Triton X-100 at room
temperature. After the blocking solution was washed
out, the cells were incubated with primary antibodies
against SPOCK1, E-cadherin, or vimentin for 60 min at
37°C and then washed with 0.1% BSA twice. After
60 min of incubation at 37°C with Cy3 Goat Anti-Rabbit
IgG (Beyotime, Shanghai, China) and then washing with
0.1% BSA, the cells were counterstained with DAPI and
imaged under a fluorescence microscope. The experi-
ments were performed in triplicate.
Flow cytometric analysis of cell apoptosis
The extent of apoptosis was measured with an Annexin
V-APC Apoptosis Detection kit (BD Biosciences) ac-
cording to the manufacturer′s instructions. Untrans-
fected and transfected GBC-SD, SGC-996, and NOZ
cells were collected, washed with cold PBS twice, gently
resuspended in 100 μL of 1× binding buffer containing
2.5 μL APC-conjugated annexin-V and 1 μL of 100 μg/mL
PI, and then incubated at room temperature in the dark
for 15 min. The stained cells were analyzed by flow cytom-
etry (BD Biosciences). The experiments were performed
in triplicate.
Nuclear morphology assay
Untransfected and transfected GBC-SD and NOZ cells
were seeded in 6-well culture plates. After 48 h, the cells
were washed with PBS, fixed in MeOH-HOAc (3:1, v/v)
for 10 min at 4°C, and stained with Hoechst 33342
(5 μg/mL in PBS) for 5 min at room temperature. The
stained cells were then examined under a fluorescence
microscope. The experiments were performed in triplicate.
Antibodies and western blotting
A rabbit anti-SPOCK1 antibody was purchased from
Abcam (MA, USA). Rabbit anti-Snail, anti-vimentin, anti-
N-cadherin, anti-E-cadherin, anti-PI3K, anti-phospho-
PI3K (Tyr607), anti-Akt, anti-phospho-Akt (Ser473), anti-
Bax, anti-Bcl-2, anti-cleaved caspase 3 and 9, anti-poly
(adenosine diphosphate-ribose) polymerase (PARP), and
anti-GADPH antibodies were obtained from Cell Signaling
Technology (Danvers, USA). Briefly, equal quantities of
cellular proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred onto poly-
vinylidene difluoride membranes, and immunoblotted
with a primary antibody. After incubation with a second-
ary antibody, blots were visualized by enhanced chemilu-
minescence (Millipore, Billerica, MA). GADPH was used
as the loading control.
Statistical analysis
All statistical analyses were performed using SPSS 19.0
software. SPOCK1 mRNA levels in tumor and paired
nontumor tissues were compared with the paired Stu-
dent’s t-test. The independent Student’s t-test was used
to compare the means of two groups. The Pearson χ2
test was used to analyze the association of SPOCK1 ex-
pression with clinicopathologic parameters. Kaplan-
Meier plots and log-rank tests were used for survival
analysis. Univariate and multivariate Cox proportional
hazard regression models were used to analyze inde-
pendent prognostic factors. Each experimental value was
expressed as the mean ± standard deviation (SD). Differ-
ences between groups were considered significant at P <
0.05. All data points represent the mean of triplicate
data points.Results
Clinical significance of SPOCK1 in GBC
To assess the role of SPOCK1 in GBC, SPOCK1 mRNA
expression in 28 pairs of GBCs (tumor and correspond-
ing nontumor tissues) was compared by qRT-PCR. The
relative expression level of SPOCK1 was significantly
higher in tumor tissues compared with that in their non-
tumor counterparts (P = 0.016) (Figure 1A and B). Fur-
thermore, protein expression levels of SPOCK1 were
measured in 64 samples of archived paraffin-embedded
GBC tissues and 60 cholecystitis gallbladder epithelial
tissues by immunohistochemistry (Figure 1C). SPOCK1
expression was significantly higher in tumor tissues
compared with that in cholelithiasis tissues (P = 0.002)
(Table 1). A clinicopathological association study of the 64
GBCs found that SPOCK1 was significantly associated
with histological differentiation (P = 0.012) (Figure 1C)
and lymph node metastasis (P < 0.001) (Table 2). GBC pa-
tients who developed metastasis showed significantly
higher immunoreaction scores for SPOCK1 than those
without metastasis (P < 0.001) (Figure 1D), which implies
that SPOCK1 might play a role in metastasis. More intri-
guingly, positivity for SPOCK1 was correlated significantly
with shorter overall survival (OS) (log rank, 11.301; P =
0.001) (Figure 1E). Multivariate Cox regression analysis
further revealed that SPOCK1 was an independent prog-
nostic marker for the OS time of GBC patients (hazard ra-
tio, 0.378; 95% confidence interval, 0.164–0.871; P = 0.022)
(Table 3).
Figure 1 Clinical significance of SPOCK1 in human GBC. (A) Scatterplots of the relative expression of SPOCK1 in GBC tissues and their
matched nontumor counterparts. SPOCK1 expression was calculated and is expressed as the SPOCK1/GADPH expression ratio (2-ΔCT).
(B) Comparison of the SPOCK1 expression level between GBC tissues and their corresponding nontumor tissues. (C) Representative image of GBC
staining with an anti-SPOCK1 antibody. (a, b) Weak expression of SPOCK1 in well and moderately differentiated GBC tissues; (c) strong expression
of SPOCK1 in poorly differentiated GBC tissues (scale bar, 100 μm). (D) Scatterplots of the average staining scores of SPOCK1 expression in
patients with or without metastasis. (E) Kaplan-Meier overall survival curve of GBC patients correlated with SPOCK1 expression.
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To explore the role of SPOCK1 in the progression of
GBC, we detected the endogenous expression of SPOCK1
in tumor and nontumor tissues, and five GBC cell lines by
RT-PCR and western blotting. Among five GBC cell lines,
SPOCK1 expression was overexpressed in GBC-SD and
NOZ cells and gradually decreased in OCUG, EH-GB-1,




Negative (0) Weakly stained (1–
Cholecystitis tissues 60 48 12
Gallbladder cancer 64 7 17observed in western blotting (Figure 2B). In addition,
SPOCK1 protein immunostaining was mainly found on
the cell membrane and in the cytoplasm of GBC cells
(Figure 2C). We chose GBC-SD and NOZ cell lines for
stable transfection with shRNA lentivirus vectors to-
ward SPOCK1, and SGC-996 cell lines for stable trans-
fection with SPOCK1-expression vector. The effect of
shRNA transduction on the expression of SPOCK1 wasin GBC
p
2) Moderately stained (3) Strongly stained (4–6)
0 0 0.002
11 29
Table 2 Association of SPOCK1 expression with the clinicopathological characteristics of GBC
Variable Category No. of
cases
SPOCK1
No. of positive cases (%) χ2 p
Age <60 18 11 (61.1) 0.021 0.886
≥60 46 29 (59.2)
Sex Male 22 14 (63.6) 0.018 0.892
Female 42 26 (61.9)
Jaundice Present 33 21 (63.6) 0.038 0.846
Absent 31 19 (61.3)
Associated gallstone Present 42 25 (59.5) 0.462 0.497
Absent 22 15 (68.2)
Histology differentiation Well or moderate 43 22 (51.2) 7.187 0.012
Poor 21 18 (85.7)
Tumor invasion(AJCC) Tis-T1 15 7 (46.7) 2.096 0.148
T2-T4 49 33 (67.3)
Lymph node metastasis Absent 43 20 (46.5) 14.293 <0.001
Present 21 20 (95.2)
TNM stage(AJCC) 0-I 15 7 (46.7) 2.096 0.148
II-IV 49 33 (67.3)
Total 64 40 (62.5)
Bold values indicate statistical significance, P < 0.05.
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knockdowns by shSPOCK1-1 in GBC-SD and NOZ cell
lines compared with those of the other two vectors
(Additional file 2: Figure S1B). We examined the lenti-
viral transduction efficiency by EGFP expression under a
microscope at 72 h after transduction (Additional file 2:
Figure S1A). The efficiency of lentiviral transduction in
both GBC-SD and NOZ cell lines was higher than 90%.
The transfection efficiency was comfirmed by RT-PCRTable 3 Univariate and multivariate analysis of the associatio
SPOCK1 expression in GBC patients
Variable Univariable
HR (95% C
Age (<60 vs. ≥60) 0.502 (0.240
Sex (male vs. female) 1.076 (0.575
Jaundice (present vs. absent) 1.324 (0.780
Associated gallstone (present vs. absent) 0.550 (0.294
Histology differentiation (well or moderate vs. poor) 0.431 (0.23
Tumor invasion (AJCC) (Tis-T1 vs.T2-T4) 6.272 (2.50
Lymph node metastasis (present vs. absent) 6.278 (3.12
TNM stage (AJCC) (0-I vs. II-IV) 6.272 (2.50
Type of surgery (curative resection vs. palliative) 0.687 (0.361
Overexpression of SPOCK1 in tumor
(Negative vs. positive) 0.346 (0.18
Bold values indicate statistical significance, P < 0.05, CI, confidence interval; HR, haza(Additional file 2: Figure S1B) and western blotting
(Figure 2D).
Effects of SPOCK1 overexpression and knockdown on
GBC cell growth in vitro and in vivo
The tumorigenic ability of SPOCK1 was assessed by
CCK-8 and colony formation assays. Figure 3A shows
that the proliferation of GBC-SD and NOZ cells was sig-
nificantly inhibited by SPOCK1 depletion (P < 0.001).n of prognosis with clinicopathologic parameters and
analysis Multivariable analysis
I) p HR (95% CI) p
-1.051) 0.062 - -
-2.017) 0.818 - -
-2.409) 0.356 - -
-1.030) 0.058 - -
3-0.796) 0.006 1.480 (0.721-3.038) 0.286
7-15.691) <0.001 8.136 (2.584-25.619) <0.001
6-12.611) <0.001 2.653 (1.100-6.396) 0.030
7-15.691) <0.001 8.136 (2.584-25.619) <0.001
-1.307) 0.249 - -
1-0.659) 0.001 0.378 (0.164-0.871) 0.022
rd ratio.
Figure 2 Expression of SPOCK1 in GBC cell lines. (A and B) mRNA and protein expression of SPOCK1 in tumor and nontumor tissues, and
GBC cell lines GBC-SD, NOZ, SGC-996, OCUG, and EH-GB-1. (C) Immunofluorescence images of SPOCK1 (red) and DAPI (blue) staining in GBC-SD
and NOZ cells (×200). (D) Western blot analysis of SPOCK1 expression in SPOCK1-depleting GBC-SD and NOZ cells and SPOCK1 overexpressing
SGC-996 cells. GADPH was used as the loading control.
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the colony formation assay showed that the number of
colonies formed by GBC-SD and NOZ cells was signifi-
cantly decreased by silencing SPOCK1 (Figure 3B) (P <
0.01). To investigate the mechanisms underlying altered
cell growth, EdU retention assays were performed to
examine the regulatory effect of SPOCK1 on DNA replica-
tion. Following transfection with Lv-shSPOCK1, the per-
centage of EdU-positive cells was reduced in GBC-SD and
NOZ cells compared to the controls (Figure 3C). Further-
more, to assess the effects of SPOCK1 on GBC growth
in vivo, SPOCK1-depleted or control NOZ cells were
injected into the left axilla of nude mice, and then the
tumor volume was monitored. Our results showed that
the growth of SPOCK1-depleted xenografts was signifi-
cantly inhibited compared with that of tumors formed by
control cells (Figure 4A and B). Moreover, IHC staining
showed less Ki-67 positive cells in SPOCK1-depleted inoc-
ulated tumor tissues (Additional file 3: Figure S2B). Con-
versely, compared with empty vector-transfected cells,
SPOCK1-transfected cells showed increased growthrates (Figure 3A) (P < 0.01), greater colony forming abil-
ities (Figure 3B) (P < 0.001), increased DNA replication
(Figure 3C), larger mean tumor volume (Figure 4B)
(P < 0.05) and higher Ki-67 index (Additional file 3:
Figure S2B). Collectively, our data demonstrate that
SPOCK1 plays a potential role in promoting cell prolif-
eration both in vitro and in vivo.
SPOCK1 promotes cell migration and invasion in vitro
and in vivo by inducing EMT
To investigate the effects of SPOCK1 on cancer cell mi-
gration and invasion, we performed in vitro wound healing
and transwell migration assays, and an in vivo metastasis
assay. Both wound healing and transwell migration assays
showed that the invasive capability of control cells was
greater than that of the transfected cells, while overexpres-
sion of SPOCK1 in SGC-996 cells showed the opposite ef-
fect (Figure 5A and B). These results indicate that SPOCK1
increases cell invasion. To determine whether SPOCK1 pro-
moted the invasiveness of GBC through EMT processes, we
detected EMT biomarkers by immunofluorescence analysis
Figure 3 Effect of SPOCK1 overexpression and silencing on the growth of GBC cells in vitro. (A) The cells growth rates were determined
by CCK-8 proliferation assays at various time points (*P < 0.05, **P < 0.01, and ***P < 0.001). (B) Representative images of colony formation induced
by Lv-shNC, Lv-shSPOCK1, MOCK-SGC-996, and SPOCK1-SGC-996 cells. The numbers of colonies were calculated and are depicted in the bar chart
(*P < 0.05, **P < 0.01, and ***P < 0.001). (C) Knockdown of SPOCK1 expression inhibited DNA replication in GBC-SD and NOZ cells compared to
control as determined by the EdU incorporation assay. Elevated expression of SPOCK1 increased DNA replication in SGC-996 cells.
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GBC-SD and NOZ cells transfected with shSPOCK1
expressed high levels of E-cadherin, which is characteristic
of epithelial cells. However, in GBC cell lines transfected
with shSPOCK1, there was a decrease in the expression of
Snail, Vimentin and N-cadherin, indicating a mesenchy-
mal phenotype (Figure 5C and D). Overexpression of
SPOCK1 could reverse this phenotype (Figure 5C and D).
To confirm these findings in vivo, we used a peritoneal
metastasis model in nude mice. Mice injected withSPOCK1-depleted NOZ cells exhibited few ascites
(Figure 6A) at 4 weeks after implantation. After dissecting
out the peritoneal metastatic tumors, the tumors were an-
alyzed by histology (Figure 6C). In the immunohistochem-
ical analysis, the Lv-shSPOCK1 group showed very light
staining of SPOCK1 and vimentin (Figure 6C), which was
consistent with the results of western blotting and im-
munofluorescence analysis in vitro. Our data suggest that
SPOCK1 promotes tumor invasion and metastasis via
inducing EMT.
Figure 4 Effect of SPOCK1 overexpression and silencing on the growth of GBC cells in vivo. (A and C) Representative examples of tumors
formed in nude mice injected with the indicated cells. (B and D) Tumor growth curves are summarized in the line chart. A statistical plot of
average tumor weights in the subcutaneous xenograft model (*P < 0.05, **P < 0.01, and ***P < 0.001).
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To explore the molecular mechanism by which SPOCK1
regulated the proliferation and metastasis of GBC cells,
we investigated the effect of SPOCK1 on apoptosis. The
apoptotic indexes of knockdown control cells (Lv-shNC)
and SPOCK1-silenced cells (Lv-shSPOCK1) were 4.86%
and 15.43% (GBC-SD, P < 0.01), 5.3% and 10.77% (NOZ,
P < 0.05), respectively (Figure 7A). Furthermore, the
apoptotic index of SPOCK1 transfectants in SGC-996
cells was lower than that of vector transfectants
(Additional file 4: Figure S3A). These results indicate
that silencing SPOCK1 restores the cellular response
to apoptotic stimuli. Phase contrast microscopic obser-
vation of SPOCK1-silenced cells showed that the
growth inhibitory effect was accompanied by cell
shrinkage (Figure 7B), suggesting apoptotic cell death.
Control and negative control cells were normal with
round and homogeneous nuclei, whereas SPOCK1-
silenced cells exhibited the hallmark characteristics of
apoptosis with cell shrinkage, and nuclear condensa-
tion and fragmentation (Figure 7B).
SPOCK1 exerts an anti-apoptotic effect through the
PI3K/Akt pathway
Tumor cells resist cell death through either disruption of
apoptotic processes or activation of survival signals. In
general, survival signals are mediated by the PI3K/Akt
pathway [15]. Deregulation of Akt phosphorylation repre-
sents an important anti-apoptotic mechanism in various
cancers. Activated Akt can phosphorylate a wide variety of
substrate proteins including Bax, a pro-apoptotic memberof the Bcl-2 protein family, which is suppressed by
phosphorylation. Bax inactivation maintains the integ-
rity of the mitochondrial membrane, which activates
caspase-9, caspase-3, and PARP [16]. Therefore, we ex-
amined whether SPOCK1 inhibits apoptosis via PI3K
and Akt phosphorylation. Compared with control cells,
the levels of both phosphorylated PI3K (Tyr607) and
Akt (Ser473) were decreased in SPOCK1-transfected
cells, while their total protein levels were unaffected.
Inactivated Akt subsequently regulates Bcl-2 family pro-
teins. As a result, the subsequent cleavages of caspase-9,
caspase-3, and PARP were all increased in SPOCK1
knockdown cells compared with those in control cells
(Figure 7C). The PI3K and Akt phosphorylation were re-
versed when SPOCK1 was overexpressed in SGC-996 cells
(Additional file 4: Figure S3B). These results indicated that
the PI3K/Akt pathway might participate in the SPOCK1-
induced anti-apoptotic effect on GBC cells.
Discussion
GBC is a highly lethal disease, and most afflicted individ-
uals do not survive because of local tumor spread and
invasion. Therefore, efforts are urgently needed to iden-
tify reliable tumor markers for early detection and
cancer-specific cellular targets for novel therapeutic ap-
proaches. SPOCK1 is a proteoglycan that was first iso-
lated in human testes and initially called ‘tesyican’. It is
dysregulated in many organs and tissues including the
brain, cartilage, vascular endothelium, lymphocytes, and
neuromuscular junctions [11,12,17]. Recently, SPOCK1
was also found to be overexpressed in hepatocellular
Figure 5 (See legend on next page.)
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Figure 5 SPOCK1 promotes tumor invasion and metastasis in vitro by inducing EMT. (A) Wound closure was delayed in Lv-shSPOCK1-
transduced cells compared with that in CTRL and Lv-shNC cells at 48 h in both GBC-SD and NOZ cells. Overexpression of SPOCK1 in SGC-996 cells had the
opposite effects (*P< 0.05, **P< 0.01, and ***P< 0.001). (B) Matrigel invasion assay of CTRL, Lv-shNC, Lv-shSPOCK1, MOCK, and SPOCK1 transfectants cells.
The number of invaded cells was calculated and is depicted in the bar chart. (*P< 0.05, **P< 0.01, and ***P < 0.001). (C and D) The protein expression of
Snail, vimentin, N-cadherin and E-cadherin in the indicated cells was examined by western blotting. The protein expression of vementin and E-cadherin
was examined by immunofluorescence analysis. The red signal represents staining for E-cadherin or vimentin. Nuclei were counterstained with DAPI.
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overexpressed in several other types of carcinoma, it has
not been linked to GBC or any other malignancy of the
biliary tract.
Our clinical association study found that SPOCK1 was
highly expressed in GBC tissues compared with that in
their nontumor counterparts, indicating that SPOCK1
might play a role in GBC development. Moreover, immu-
nohistochemistry showed that overexpression of SPOCK1
was significantly associated with histological differenti-
ation, lymph node metastasis, and a shorter OS time of
GBC patients. Cox proportional hazard regression analysis
further identified SPOCK1 as an independent factor for
poor prognosis. Because SPOCK1 is a secreted protein
that can be detected at very low levels in normal tissues,
SPOCK1 overexpression in GBC may serve as a biomarker
for early detection and precise prognoses.
In this study, we confirmed that SPOCK1 was expressed
in GBC by qRT-PCR, western blotting, and immunofluor-
escence, which represented an ideal model to study theFigure 6 SPOCK1 promotes tumor invasion and metastasis in vivo by
evaluate the effect of Lv-shSPOCK1 cells on tumor metastasis. Mice that rec
after implantation. (B) The tumor incidence rate during the 4-week observa
and vimentin in tumor tissues of the peritoneal metastasis model.role and molecular mechanisms of SPOCK1. A series of
in vitro and in vivo assays showed that cancer cell growth,
DNA replication and the colony formation capability were
significantly decreased by inhibition of SPOCK1, suggest-
ing its role in cancer cell proliferation and tumor growth.
Additionally, we found that SPOCK1 induced GBC cells
migration and invasion, indicating that SPOCK1 might
undergo metastasis-related genetic alteration in GBC cells.
Metastasis is a multistep cellular process and the most
common cause of death in GBC patients. This process in-
volves the spread of tumor cells from a primary tumor to
a secondary site within the body. It usually involves a var-
iety of complicated molecular and cellular factors related
to cell proliferation and migration, degradation of the
basement membrane, invasion, adhesion and angiogenesis.
At the molecular level, the acquisition of genetic and/or
epigenetic alterations, along with the cooperation of stro-
mal cells, contribute to cancer metastasis [19,20].
SPOCK1 promotes cancer cell migration by induction of
EMT [21]. EMT is a crucial step in tumor progression andinducing EMT. (A) An in vivo metastasis assay was performed to
eived SPOCK1-depleted NOZ cells exhibited little ascites at 4 weeks
tion period. (C) Immunohistochemical staining of SPOCK1, E-cadherin,
Figure 7 (See legend on next page.)
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Figure 7 SPOCK1 exerts an anti-apoptotic effect via the PI3K/Akt pathway. (A) Apoptosis was determined by flow cytometry. Cells stained
with annexin-V-APC were considered as apoptotic. The apoptotic index was defined as the percentage of apoptotic cells. (B) Apoptotic changes in the
nuclear morphology of GBC-SD and NOZ cells as indicated by Hoechst 44322 staining (blue). The apoptotic index, defined as the percentage of apoptotic
cells, was calculated and is summarized in the bar chart (*P< 0.05, **P< 0.01, and ***P< 0.001). (C) The levels of phosphorylated PI3K (Tyr607), total PI3K,
phosphorylated Akt (Ser473), total Akt, Bax, Bcl-2, caspase-9, caspase-3, and PARP were detected in CTRL, Lv-shNC, and Lv-shSPOCK1 cells by western blot
analysis. GADPH was used as the loading control.
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During this process, epithelial cells lose their properties and
acquire mesenchymal phenotypes. Mesenchymal phenotype
cells exhibit increased expression of mesenchymal-related
markers, such as vimentin, and decreased expression of
epithelial-related markers such as E-cadherin [22,23]. In the
current study, we showed that suppressed expression of
SPOCK1 induced EMT by elevating expression of the epi-
thelial marker E-cadherin and reducing expression of the
mesenchymal marker Snail, vimentin and N-cadherin. Our
findings indicate that SPOCK1 may drive EMT in cancer
cells, resulting in metastasis.
Further experiments revealed that SPOCK1-enhanced
tumor cell survival may be attributable to its anti-
apoptotic effect. Our data show that SPOCK1 contributes
to anti-apoptotic effects through inactivation of the PI3K/
Akt pathway, which subsequently activates the caspase 9/
caspase 3/PARP pathway. Inhibition of apoptosis is one of
the major mechanisms in cancer development and ultim-
ately leads to the expansion of neoplastic cells with
deregulated proliferation and accumulation of genetic in-
stability and mutations [24]. Therefore, impaired GBC cell
growth and metastasis due to SPOCK1 knockdown can be
explained, at least in part, by inactivation of the PI3K/Akt
pathway. Previous reports show that PI3K/Akt is a clas-
sical signaling pathway [25-27], and its activation induces
cell growth [28,29], promotes EMT [30], and stimulates
Bax-mediated signaling for apoptosis progression. Our re-
sults suggest that inactivation of PI3K/Akt signaling is re-
sponsible for SPOCK1 shRNA-mediated suppression of
tumor cell proliferation, migration, invasion, and EMT.
Because SPOCK1 belongs to the Ca2+-binding proteo-
glycan family, some of these effects may be mediated by
the glycan segment of SPOCK1. Increasing evidence has
shown that glycan specifically interacts with growth fac-
tors, chemokines, and the matrix architecture [31]. Cancer
cells usurp these properties to gain a survival advantage
and invade tissues throughout the organism. For example,
the glycan segment of perlecan protects fibroblast growth
factor 2 from proteolytic degradation and potentiates its
angiogenic role [32]. In addition to the steady-state proper-
ties of glycan, changes in glycan segments affect cancer de-
velopment, such as glycosylation and depolymerization.
Heparanase-induced depolymerization can release fibro-
blast growth factor 2 from perlecan to facilitate vascularsprouting during angiogenesis [33]. Some of these charac-
teristics of perlecan may be shared by other pericellular
proteoglycans such as agrin, collagen type XVIII, and
SPOCK1. However, to determine whether SPOCK1 per-
forms its functions by working alone or in concert with
other partner molecules, it will be important to identify the
portion of the proteoglycan that mediates the interaction.
A better understanding of the oncogenic mechanisms
of SPOCK1 during GBC initiation and progression may
have implications for future patient treatments.Conclusions
We have demonstrated that the expression of SPOCK1 is
associated with histological differentiation, lymph node me-
tastasis, and the OS time of GBC patients. SPOCK1 pro-
motes GBC cell proliferation and metastasis both in vitro
and in vivo. We hypothesize that SPOCK1 might play an
important role during the EMT of GBC cells, which results
in metastasis. Moreover, SPOCK1 contributes to anti-
apoptotic effects through inactivation of the PI3K/Akt
pathway. These observations support our belief that
SPOCK1 may serve as an oncogene in GBC pathogenesis.Additional files
Additional file 1: Table S1. The nucleotides applied in the study.
Additional file 2: Figure S1. RT-PCR of the transfection efficiency in
GBC cell lines. (A) The transduction efficiency was determined at 3 days
after infection with lentiviruses at a multiplicity of infection of 50. The
transduced cells labeled with EGFP were observed under a fluorescence
microscope. Light micrograph (upper); fluorescent micrograph (lower)
(×100). (B) RT-PCR were performed to detect SPOCK1 expression in the
indicated cells (*P < 0.05, **P < 0.01, and ***P < 0.001).
Additional file 3: Figure S2. Association of SPOCK1 expression on the
growth of GBC cells in vivo. (A and B) Photograph of a subcutaneous
xenograft model of human GBC in mice. (C) Immunohistochemical
staining of Ki-67in tumor tissues of the subcutaneous xenograft model.
Additional file 4: Figure S3. SPOCK1 exerts an anti-apoptotic effect via
the PI3K/Akt pathway in SGC-996 cells. (A) Apoptosis was determined in
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apoptotic index was defined as the percentage of apoptotic cells. (B)
The levels of phosphorylated PI3K (Tyr607), total PI3K, phosphorylated Akt
(Ser473), total Akt were detected in empty vector- and SPOCK1-transfected
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